Sanofi is scheduled to report results for the third quarter on Friday. Here is what you need to know.
SALES FORECAST: The French drugmaker is expected to report third-quarter net sales of 13.25 billion euros ($14.78 billion), according to consensus estimates compiled by Vara. For the same period last year, the company's sales came to 12.43 billion euros.
EARNINGS FORECAST: Analysts expect Sanofi's business earnings per share--one of the company's preferred profit metrics--to be 2.81 euros, according to the same consensus. The company's business EPS stood at 2.91 euros in the third quarter of 2025.
Shares in Sanofi fell 3.3% during the third quarter. Since the start of the year through Wednesday's close, they fell 8.7%.
WHAT TO WATCH
--DEALMAKING: Sanofi's plans for upcoming deal activity will be at the top of investors' minds, analysts at Jefferies wrote in a note to clients. The company recently expanded its alliance with U.S. peer Regeneron Pharmaceuticals, an important first step toward addressing the sales hole it will face when Dupixent--a blockbuster anti-inflammatory drug jointly developed by the two companies--goes off patent in the early 2030s, Jefferies said. During an earnings call in July, Sanofi's new chief executive, Belen Garijo, signaled the company might have more appetite for bigger deals than in the past under her watch. Sanofi's new research-and-development head, Paulo Fontoura, joined in September and investors might want to hear about his priorities, Citi analysts said.
--OUTLOOK: The company raised its 2026 guidance in July and now expects sales to grow by around 10% at constant exchange rates. Some analysts like Citi's see scope for another upgrade, while others such as J.P. Morgan's anticipate guidance to be reiterated.
--VACCINES: GSK flagged weakness in its vaccine segment earlier this week, with sales at the business falling short of analysts' expectations in the third quarter. Sanofi also has a sizable vaccines unit and UBS analysts said they expect a 13% sales decline for the third quarter due to the atypical timing of the flu season, and pressure from competition and slower-than-expected penetration of its Beyfortus shot for respiratory syncytial virus.
Comments